Harris & Harris GroupSince 1983, Harris & Harris Group has a strong reputation for investing in companies with proprietary technologies. Their primary focus is interdisciplinary life sciences enterprises, where innovative biology intersects with innovation in areas such as electronics, chemistry, physics, materials, information, technology, engineering and mathematics. Harris & Harris Group stands out from its competitors because its investments are not divided into specific funds. Currently, they invest in 25 small portfolio companies with total investments equating to $172 million. Distinctive approach in biotechnology We see lucrative potential in Harris & Harris Group due to its unique focus on creation, incubation and creation of transformative companies based on disruptive science. Their focus on biology, which has become their approach to creating high-value life insurance companies, sets them apart from their competitors. They believe in interdisciplinary innovation that will solve the challenges of current and future life. Tulane Endowment wants to invest in innovations that will radically change the future and improve people's lives. We are also interested in the Harris & Harris group and the biotechnology industry for its youth and rapid growth. With an expected growth of 10.8 percent over the next 10 years, we believe demand will increase. Tulane Endowment seeks investments in industry segments experiencing a rapid pace of technological change, such as Harris & Harris. We have seen in recent years the demand for therapeutics and genetically modified crops increase, and we therefore believe that this industry will remain in the growth phase of its economic life cycle throughout our investment and.... .. middle of paper ......ed to other brands. Tulane Endowment considers Repairogen an excellent investment opportunity and seeks to support such start-ups, as there is ample room for development and numerous growth opportunities, both domestically and internationally. ValuationHarris & Harris Group valued Repairogen at $1,368,055 using comparables. This is a high valuation for a company in the R&D stage. However, this company offers a very unique product that attracts customers from the health and cosmetic industries. Repairogen's exit strategy is a merger or acquisition, which is a typical exit strategy for the cosmetics industry and a safer exit strategy than an IPO. Tulane Endowment is very pleased to provide funding to this company as we believe Repairogen has ample opportunity to expand globally and gain a competitive advantage once it enters the cosmetics market..